title: The impact of skin disease following renal transplantation on quality of life.
abstract: BACKGROUND
  The immunosuppressive therapy a patient requires to sustain a functioning renal allograft in the long term is associated with various skin complications. While quality of life (QoL) after renal transplantation has been studied, no publications document the effect of post-transplant dermatological complications on QoL.
  
  
  OBJECTIVE
  The objective of the study was to document the prevalence of the skin diseases that commonly occur in association with post-transplant immunosuppression. A general dermatological quality of life questionnaire, the Dermatology Life Quality Index (DLQI), was used to assess the QoL effect of these cutaneous complications. The study was designed to examine further the impact of age, sex, duration since transplant and immunosuppressive regimen on the DLQI score of renal transplant recipients (RTR).
  
  
  METHODS
  One hundred and seventy-three RTR completed the DLQI, were interviewed and examined for evidence of common post-transplant skin diseases.
  
  
  RESULTS
  Sixteen per cent of RTR had DLQI scores >6, reflecting a significant impact on their QoL. Dry skin, itch, hypertrichosis, sebaceous gland hyperplasia, acne, genital warts and a history of >4 herpes simplex virus type 1 infections in the past year were all found to have a significant impact on the quality of life (P < 0.05). Multivariate analysis revealed that the greatest impact on QoL was in RTR who were younger, female and with multiple skin problems (P < 0.05).
  
  
  CONCLUSIONS
  The dermatological complications of immunosuppressive therapy are common in RTR and can significantly impair QoL in certain individuals. Visible, infectious and cosmetic skin problems had most impact on QoL while a history of skin cancer had a lesser impact. Early dermatological referral and careful choice of immunosuppression may enhance the QoL, particularly in young and female RTR.
authors.affiliation: Department of Dermatology, Beaumont Hospital, Dublin 9, Ireland. fergalmoloney@eircom.net
authors.forename: F J
authors.initials: FJ
authors.lastname: Moloney
authors.forename: S
authors.initials: S
authors.lastname: Keane
authors.forename: P
authors.initials: P
authors.lastname: O'Kelly
authors.forename: P J
authors.initials: PJ
authors.lastname: Conlon
authors.forename: G M
authors.initials: GM
authors.lastname: Murphy
mesh_terms: D000328:Adult; D000367:Age Factors; D005260:Female; D006561:Herpes Simplex / Q000150:complications; D018259:Herpesvirus 1, Human; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D007676:Kidney Failure, Chronic / Q000276:immunology / Q000523:psychology / Q000601:surgery; D016030:Kidney Transplantation / Q000009:adverse effects / Q000523:psychology; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D015995:Prevalence; D011788:Quality of Life; D012737:Sex Factors; D012871:Skin Diseases / Q000150:complications / Q000209:etiology / Q000523:psychology; D012878:Skin Neoplasms / Q000150:complications / Q000209:etiology / Q000523:psychology; D011795:Surveys and Questionnaires; D013997:Time Factors
chemical_list: D007166:Immunosuppressive Agents